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Concurrent inhibition of enzymatic activity and
NF-Y-mediated transcription of Topoisomerase-IIa
by bis-DemethoxyCurcumin in cancer cells
S Belluti1, V Basile1, P Benatti1, E Ferrari2, G Marverti3 and C Imbriano*,1
Topoisomerases-IIa (TOP2A) enzyme is essential for cell viability due to its fundamental role in DNA metabolism and in
chromatin organization during interphase and mitosis. TOP2A expression is finely regulated at the transcriptional level through
the binding of the CCAAT-transcription factor NF-Y to its promoter. Overexpression and/or amplification of TOP2A have been
observed in many types of cancers. For this reason, TOP2A is the target of the most widely successful drugs in cancer
chemotherapy, such as TOP2A poisons, which stabilize TOP2A-DNA cleavage complexes and create DSBs, leading to
chromosome damage and cell death. We previously reported that the Curcumin-derivative bis-DemethoxyCurcumin (bDMC) is an
anti-proliferative agent that inhibits cell growth by concomitant G1/S and G2/M arrest. Here we showed that bDMC irreversibly
induces DSBs in cancer cells, but not in normal cells, by targeting TOP2A activity and expression. TOP2A ablation by siRNA
corroborates its contribution to apoptosis induced by bDMC. Short-term exposure to bDMC induces retention of TOP2A-DNA
intermediates, while longer exposure inhibits TOP2A transcription by affecting expression and sub-cellular localization of NF-Y
subunits. ChIP analysis highlighted reduced recruitment of NF-Y to TOP2A regulatory regions, concomitantly to histone
deacetylation and decreased gene transcription. Our findings suggest that the dual activity of bDMC on TOP2A represents a
novel therapeutic strategy to induce persistent apoptosis in cancer cells and identify NF-Y regulation as a promising approach in
anti-cancer therapy.
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Mammalian cells express two Topoisomerase II (TOP2)
enzymes, TOP2A and TOP2B, but only the first is essential
for cellular viability.1,2 TOP2A has a key physiological function
in DNA metabolism of eukaryotic cells and has a structural
role in chromatin organization during interphase and
mitosis.3,4 The development of TOP2A-depleted mice termi-
nates at the four- or eight-cell stage because of chromosome
segregation defects.5 TOP2A expression is low in quiescent
cells and increases when cells are stimulated to re-enter the
growth phase of the cell cycle: its levels rise throughout the S
phase and peak during G2/M phase.6–8 The expression of
human TOP2A mRNA is controlled by its promoter region,
whose activity is regulated through cis-acting elements within
the first 617 base pairs.9 Among multiple transcription factors
controlling TOP2A transcription throughout the cell cycle, Sp
and NF-Y have been shown to bind GC consensus sites and
four inverted CCAAT boxes (ICB1–ICB4), respectively.10–12
NF-Y is a heterotrimeric complex composed of three
conserved subunits, NF-YA, NF-YB and NF-YC.13 NF-YA
interacts with the NF-YB/NF-YC heterodimer and determines
specific NF-Y binding to the CCAAT box. Although NF-Y acts
as a transcriptional activator of TOP2A, its binding to ICB2 has
been described to downregulate the promoter activity by
confluence arrest.14
TOP2A transcription can be inhibited by wt p53 and the
disruption of ICBs abolishes the p53-dependent downregulation
of TOP2A.15,16 In addition, p53-independent mechanisms can
lead to decreased TOP2A mRNA levels through reduced
NF-Y binding to ICB1.15
Increased TOP2A protein levels have been detected in
cancer cells compared with non-malignant cells, although a
strong heterogeneity of TOP2A expression within different
cancer cells has been observed.17 For this reason, TOP2A is
the target for some of the most widely successful drugs used
to treat human cancers.18,19
Two different classes of drugs targeting TOP2A have been
described: the first one, referred to as TOP2A poisons,
increases the concentration of covalent enzyme-cleaved DNA
complexes and generates DNA strand breaks. The second
class is composed by catalytic TOP2 inhibitors, compounds
that prevent TOP2 from carrying out its physiological
enzymatic activity.18
TOP2-DNA covalent complexes have severe effects on cell
proliferation and viability: TOP2 poisons block both replication
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and transcription processes and lead to the activation of
apoptosis by inducing DNA strand breaks.20–23
Although the great potential of TOP2 targeting drugs
towards multiple type of human cancers, TOP2 poisons can
lead to secondary malignancies. In particular, etoposide and
teniposide administration in chemotherapy regimens have a
high potential of generating translocations, responsible for
secondary malignancies,24,25 while anthracyclines generate
free radicals in both normal and tumor tissues, leading to bone
marrow and cardiac toxicity.26,27
Curcumin, the pigment derived from the rhizome Curcuma
longa, has demonstrated anticancer properties, attributed to
its selective cell death-inducing ability in tumor cells.28–30 The
apoptotic process seems to be initiated by DNA damage
triggered by TOP2 poisoning.31,32 Despite the possible side
effects of Curcumin on fertility and immune functions,33–35 in
the majority of normal and primary cells, it does not elicit a
cytotoxic response.
We demonstrated that the Curcumin derivative
bis-DemethoxyCurcumin (bDMC) ismore stable in physiological
condition than its lead compound, circumventing one of the
most limiting facets of Curcumin in clinical applications.36
bDMC exhibits improved cytotoxicity in ovarian cancer cells
and shows higher anti-oxidant, anti-mutagenic, anti-carcino-
genic and anti-metastatic activities than Curcumin.37,38
While Curcumin delays the mitotic exit as a consequence of
microtubule poisoning, bDMC is able to induce a concomitant
and long-lasting G1/S and mitotic cell cycle block in human
colon cancer cells. Concurrently to the cell cycle impairment,
bDMC activates a DNA-damage response, which can be
responsible for the slower kinetic in re-entering the cell cycle
after the release.36
Our present investigations focus on the activity of bDMC
as DNA-damaging agent and inhibitor of TOP2A. We
highlight that bDMC triggers DNA damage in cancer cells
by targeting TOP2A, both through inhibition of its enzymatic
activity and through repression of its NF-Y-dependent
transcription.
Results
Effect of bDMC on proliferation and cell cycle distribution
in cancer and normal human cells. We have already
shown that bDMC treatment induces a concomitant G1/S
and long-lasting mitotic arrest of the cell cycle of human
colon cancer cells HCT116. In particular, the passage from
early to late S is delayed when bDMC is added to
synchronized G0/G1 cells.36
In addition to cytostatic effects, cytotoxicity was observed
following bDMC administration at IC50 concentration (30 mM)
to HCT116. A time-dependent increase of SubG1 events was
detected by PI cytofluorimetric analysis in bDMC-treated
cells (from 0.6% in control cells to 5.1 and 7.5% after 16 and
24 h, respectively) (Figures 1a and b). The presence of
AnnexinV-positive cells (from 4% in dimethyl sulfoxide
(DMSO) to 20% in bDMC cells) clearly suggested that bDMC
triggers apoptotic cell death (Figure 1c). Interestingly, when
HCT116 were released from bDMC into the fresh medium,
SubG1 events raised up to about 14 and 23% after 16 and
24 h, hinting that bDMC irreversibly commits cells to apoptotic
death (Figures 1a and b). Cleavage of PARP-1 and
H2AX Ser139 phosphorylation (gH2AX) followed the time-
dependent increase of SubG1 events and further grew when
cells were released from bDMC (Figure 1d). Exposure to
bDMC induced the same effects on colorectal carcinoma
Lovo cells (Supplementary Figures S1a–c).
To investigate the cytotoxicity of bDMC against tumor
versus healthy cells, human normal fibroblasts (HF) and
hepatic fetal epithelial cells (WRL-68) were treated with 30 mM
bDMC (Figures 2a and b). No increase of SubG1 events was
detected, also when cells were released from drug incubation
(Figures 2c and e). The lack or very low expression of
gH2AX in treated and released cells further corroborates the
tumor selectivity of bDMC (Figures 2d and f). Moreover,
dose–response experiments highlighted that IC50 is signifi-
cantly higher in HF (4320mM) and WRL68 (55mM)
cells, compared with HCT116 and LOVO tumor cells
(Figures 2g and h).
bDMC induces double-strand breaks (DSBs) and
chromosome aberrations in HCT116 cells. H2AX
phosphorylation has an important role not only in apoptosis
but also in response to DSBs.39 To examine the relationship
between gH2AX and DNA damage rather than apoptosis, we
co-treated cells with bDMC and the pan-caspase inhibitor
Z-VAD. Although Z-VAD was able to completely abolish the
accumulation of SubG1 events, gH2AX was only partially
reduced compared with bDMC-treated cells, coupling its
expression to DNA damage (Figures 3A and B).
We previously demonstrated that bDMC administration for
24h resulted in ATM (ataxia telangiectasiamutated) activation.36
ATM has a major role in signal transduction in response to
DSBs,40 and once activated, it is able to phosphorylate
different proteins associated with the DNA damage response,
such as sensors, mediators, as H2AX and BRCA1, transdu-
cers and effectors of DSB, among which are ChK2, ChK1 and
p53.41Western blot analysis with Phospho-BRCA1 (Ser1524)
and Phospho-ChK1 (Ser296) antibodies further demon-
strated the activation of a DNA damage response induced
by bDMC (Figure 3C). Pre-treatment with Wortmannin
(WORT), which is able to disrupt multiple DNA damage and
DNA repair mechanisms via inhibition of PI3K-kinases (ATM
and DNA-PK),42–44 resulted in a clear reduction of H2AX
phosphorylation (Figure 3D). In addition, WORT determined a
robust decrease of G2/M population (from 46.3% in bDMC-
treated cells to 31.2% in WORT-bDMC-treated cells) and an
increase of G0/G1 events (from 34.4 to 44.9%), hinting that
the activation of the DNA damage checkpoint occurs in G2/M
and prevents cells from entering the next G1 phase
(Figure 3E).
Fluorescent-activated cell sorting (FACS) was used to
quantify the levels of H2AX phosphorylation in 2N and 4N
populations. Following 24 h treatment with bDMC, we
observed the accumulation of gH2AX-positive cells with a
4NDNA content (Figure 3F), presumably G2/M arrested cells.
Also HCT116/E6 cells, in which the lack of p53 causes a
robust arrest in G2/M and prevents the G1/S block following
bDMC administration,36 showed an evident time-dependent
increase of gH2AX, corroborating that DNA damaged cells are
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mainly distributed in the G2/M phase of the cell cycle
(Supplementary Figures S1d and e).
We then evaluated the ability of bDMC to cause chromo-
some aberrations. Cells were treated with DMSO or bDMC for
24h, and Giemsa-stained metaphases were analyzed: while
control cells did not show chromosome abnormalities, we
detected an average of two chromatid-type aberrations per
cell, in particular gaps and breaks, following bDMC adminis-
tration (Figure 3G). The same defects were detected in
HCT116/E6 cells (data not shown).
All together these data suggest that bDMC induces DNA
damage in G2/M cells, which are prevented from entering the
next G1 phase and presumably are then committed to
apoptosis.
bDMC inhibits TOP2a activity. TOP1 and TOP2-DNA
complexes have been observed following Curcumin adminis-
tration to K562 cells.32 Considering that bDMC has a
predicted stronger binding affinity to TOP2A compared with
Curcumin,45 we hypothesized that DNA damage and
chromosome aberrations induced by bDMC could be due
to the inhibition of TOP2A in HCT116 cells.
To test TOP2A inhibitory activity of bDMC, we performed a
cell-free TOP2A relaxation assay (Figure 4a). The kinetoplast
DNA (kDNA) was used as a specific substrate for TOP2
enzymes. In accordance with its known activity as TOP2A
poison, etoposide inhibited TOP2A-dependent decatenation.
bDMC was found to halved DNA decatenation at lower
concentrations than etoposide.
To assess whether bDMC could act as TOP2A poison, we
verified the formation of TOP2A-DNA complexes through a
band-depletion assay.46 We compared the levels of TOP2A in
the samples of each bDMC time point with or without
Micrococcal Nuclease (MNase) addition, which allows the
release of TOP2A from DNA complexes possibly induced by
bDMC. MNase digestion partially restored TOP2A levels in
cellular extracts from HCT116 treated with bDMC for 4 and
8 h, consistently with the presence of TOP2A-DNA com-
plexes. Differently, no increase was observed following
MNase addition in 16 and 24 h bDMC samples, hinting at a
different mechanism triggering TOP2A depletion (Figure 4b).
Increase of cellular levels of reactive oxygen species (ROS)
could have a role in the formation of TOP2-DNA complexes
induced by Curcumin.32 Therefore, a band-depletion assay
was performed with extracts from cells pre-treated with the
antioxidantN-acetylcisteine (NAC). Figure 4c shows that NAC
did not abolish TOP2A band depletion, ruling out that ROS
could mediate TOP2A-DNA complexes.
Figure 1 bDMC triggers irreversible cell death in HCT116 cells. (a) Cytometric cell-cycle analysis of HCT116 cells treated with 30 mM bDMC for 4, 8, 16, 24 h and released
in drug-free medium for additional 16 and 24 h (16hR and 24hR) following 24 h of bDMC treatment. (b) Percentages of SubG1 events detected by PI cytometric analysis
following the indicated time exposure to bDMC. Reported values are an average of 10 independent experiments±S.D. (c) The percentage of Annexin V-positive cells after
24 h treatment with 30mM bDMC is compared with Control (CTR) and DMSO-treated cells. Data are means of three independent experiments±S.D. (d) Western blot
expression analysis of gH2AX and cleaved PARP1 following time-dependent administration of 30-mM bDMC to HCT116 cells. Actin was used as loading control
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These data clearly suggest that bDMC induced retention of
TOP2A-DNA intermediates up to 8h, after which reduced protein
levels cannot be ascribed to bDMC activity as TOP2 poison.
bDMC impairs NF-Y-dependent gene transcription
of TOP2a. Despite MNase digestion, a time-dependent
decrease of TOP2A levels was observed following bDMC
Figure 2 bDMC does not induce cell death in human healthy cells. (a and b) Cell-cycle analysis of HF (a) and WRL-68 (b) cells treated with 30mM bDMC for the indicated
time points and released into fresh medium for additional 16, 24 or 48 h. (c) Quantification in percentage of SubG1 population in HF cells treated with bDMC and released into
fresh medium for 24 and 48 h (24hR and 48hR). Values are means of three independent experiments±S.D. (d) Expression levels of gH2AX in DMSO- and bDMC-treated and
released (R) HF cells. (e) Percentage of SubG1 population in WRL-68 cells following bDMC administration and released into drug-free medium (16hR and 24hR). Values are
means of three independent experiments±S.D. (f) Western blot analysis with anti-gH2AX and anti-actin antibodies in WRL-68 cells treated and released from bDMC for the
indicated time points. (g and h) Percentage of cell survival of HF and WRL-68 normal cells (g) and HCT116 and LOVO tumor cells (h) following administration with increasing
concentrations of bDMC for 24 h
Dual activity of bDMC on Topoisomerase-IIa
S Belluti et al
4
Cell Death and Disease
Figure 3 bDMC induces DNA damage and activates the DNA-damage response in HCT116 cells. (A) Quantification of SubG1 phase cell number following
Z-VAD/bDMC co-treatment or bDMC (30 mM) alone for 24 h. Data represent the average of three independent experiments±S.D. (B) Western blot and quantification of
gH2AX expression levels versus actin following bDMC and bDMC-Z-VAD 24-h treatments. (C) Western blot analysis of total extracts of 24-h 30-mM bDMC-treated cells
with the indicated antibodies. (D) Changes of gH2AX expression levels in cells pre-treated with WORT compared with cells treated for 24 h with bDMC. (E) Percentage of
cells throughout the different phases of the cell cycle of bDMC-treated cells before and after WORT pre-incubation. The indicated events are means of three independent
experiments±S.D. (F) Percentages of gH2AX-positive cells in 2N and 4N populations after 30-mM bDMC treatments for 24 h. (G) Representative Giemsa-stained
mitotic chromosome spread of cells treated with 30 mM DMSO (a) or bDMC (b) for 24 h. Enlargement of dashed box (c and d) shows chromosome aberrations of
bDMC-cells
Figure 4 bDMC inhibits TOP2a enzymatic activity. (a) Inhibition of TOP2A-dependent decatenation of kDNA following increasing concentrations of bDMC and Etoposide
(ETP) versus DMSO (arbitrarily set at 100%). (b) Western blot analysis of TOP2A expression after 4, 8, 16 and 24 h after 30 mM bDMC addition, with or without MNase
digestion. (c) TOP2A expression analysis of untreated and MNase-treated samples upon bDMC-NAC treatment
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administration (Figure 5a). In addition, proteasome inhibition
by MG132 did not raise TOP2A levels (Figure 5b), suggesting
that neither the formation of TOP2A-DNA complexes or
protein degradation were responsible for TOP2A halved
levels. For this reason, we analyzed TOP2A mRNA levels
after time course incubation with bDMC. Real-time RT-PCR
analysis revealed that bDMC induced a clear time-dependent
decrease of TOP2A gene transcription, with maximal
inhibition after 24 h (Figure 5c). The release from bDMC for
16 and 24 h did not restore TOP2A mRNA and protein levels
(Supplementary Figures S2a and b).
The transcription factor NF-Y is the key activator of TOP2A
and specifically binds the CCAAT boxes of its regulatory
regions. Chromatin immunoprecipitation (ChIP) experiments
were performed to investigate NF-Y binding to TOP2A
promoter after 24 h of bDMC administration. Compared with
DMSO, the binding of NF-YA and NF-YB subunits was
reduced by about 40 and 30%, respectively (Figure 5d). A
strong correlation between NF-Y binding and epigenetic
marks has been described, therefore we investigated by ChIP
the levels of acetylated histones H3 and H4 (H3ac and H4ac)
and H3K4me3, an epigenetic marker associated with active
Figure 5 Inhibition of NF-Y-mediated TOP2A transcription by bDMC. (a) TOP2A protein analysis in MNase-treated extracts following time course incubation with bDMC
(30mM). The indicated values represent the quantification of TOP2A immunoreactive bands of two independent experiments normalized to actin levels. (b) Quantification of
TOP2A expression levels (normalized to actin) following bDMC and bDMC-MG132 administration for 24 h versus DMSO (arbitrarily set at 1). (c) Real-time analysis of TOP2A
transcripts in cells treated with 30mM bDMC, represented as mRNA fold change versus DMSO (arbitrarily set at 1). GAPDH has been used as internal control. The indicated
values are mean of four independent experiments±S.D. (d) ChIP semi-quantitative PCR analysis of NF-YA, NF-YB, acetyl-H3 and acetyl-H4 binding to TOP2A promoter in
cells treated with DMSO or bDMC (30 mM) for 24 h. (e and f) ChIP real-time analysis of chromatin-associated NF-Y, acetyl-H4 and H3K4me3 to TOP2A promoter following
24-h (e) and 8-h (f) incubation with 30mM bDMC. (g) Semi-quantitative analysis of the recruitment of NF-Y and acetylated histones on p21 regulatory region cells treated for
24 h with DMSO and 30mM bDMC. (h) mRNA expression levels of p21 in 24 h bDMC-treated cells
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gene promoters, whose deposition is strongly dependent
upon the binding of NF-Y.47,48 Although H3ac was not
modified by bDMC, the levels of H4ac were reduced by
about 60% on the TOP2A promoter region (Figure 5d).
Real-time PCRs highlighted that maximum NF-Y and H4ac
reduction were induced after 8 h, while H3K4me3 showed a
decrease at 24 h, hinting that NF-Y dissociation could lead to
later effects on the chromatin structure of TOP2A promoter
and therefore on gene transcription (Figures 5e and f).
On the other hand, both H3 and H4 acetylation increased
on p21 regulatory region, consistently to its transcriptional
activation (Figures 5g and h). Taken together, these
data indicate that bDMC induces the transcriptional
repression of TOP2A by affecting NF-Y binding to its
promoter region.
bDMC affects NF-YA expression and sub-cellular
localization of NF-YB and NF-YC subunits. We next
wondered whether decreased NF-Y binding to TOP2A
CCAAT boxes could be ascribed to reduced NF-Y cellular
levels upon bDMC treatment. Total extracts were prepared
from HCT116 cells treated with DMSO and bDMC for 24 h.
Western blot analysis showed a decrease of the DNA binding
subunit NF-YA, consistently with mRNA halved levels
(Figures 6a and b); no changes were observed in NF-YB
and NF-YC expression levels (Figures 6a and b). While
NF-YA has been shown to be mainly localized in the nucleus,
NF-YB and NF-YC shuttle from the cytoplasm to the
nucleus.49 Therefore, we performed western blot analysis
of NF-Y subunits on nuclear and cytosolic fractions of
bDMC-treated cells. As shown in Figure 6c, NF-YB and
NF-YC were accumulated in the cytoplasm. A time-dependent
increase of cytosolic NF-YB and NF-YC was observed
following bDMC administration, with a maximum peak after
24 h of treatment (Figure 6d), although nuclear NF-YB and
NF-YC were reduced to minimum levels already after 8 h. To
discriminate whether nuclear export rather than import was
affected by bDMC, we co-treated cells with Leptomycin B
(LMB), a known inhibitor of CRM1 exportin: no increase of
nuclear NF-YB and NF-YC was observed in co-treated
versus bDMC-treated cells (Figure 6e). The accumulation of
nuclear p53 confirmed the efficacy of LMB treatment on
HCT116 cells. These results support the hypothesis that
bDMC induces Topo IIa transcriptional repression by
decreasing NF-YA levels and retaining NF-YB/NF-YC into
the cytoplasm.
Figure 6 bDMC affects NF-Y subunits expression and sub-cellular localization. (a) Western blot analysis of total extracts of DMSO and bDMC (30 mM)-treated cells (24 h)
with antibodies against the three NF-Y subunits. (b) Semi-quantitative RT-PCRs of NF-YA, NF-YB and NF-YC subunits following 24 h treatment with DMSO and 30 mM bDMC.
(c) Expression levels of NF-YB and NF-YC in nuclear and cytosolic fractions of HCT116 cells treated with 30 mM bDMC for 24 h. Tubulin and H3 were used as loading control
for cytosolic and nuclear extracts, respectively. (d) Time course analysis of NF-Y subunits expression in nuclear and cytoplasmic cellular compartments. (e) Nuclear expression
levels of NF-YB, NF-YC and p53 following co-incubation of 30 mM bDMCwith LMB for 8 h versus bDMC alone. Histone H3 was used as loading control. (f) Expression levels of
SP1 in total and chromatin-enriched extracts following time course incubation with 30 mM bDMC
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The transcriptional control of TOP2A gene has been shown
to be played by NF-Y in cooperation with the transcription
factor Sp1.50 For this reason, we decided to investigate
whether also Sp1 could have a role in the time-dependent
decrease of TOP2A mRNA levels. Chromatin-enriched and
whole-cell extracts were prepared following 4, 8 16 and 24 h
exposure of HCT116 cells to bDMC and western blot analysis
performed with anti-Sp1 antibody. As shown in Figure 6f,
while total Sp1 levels were already reduced at 8 h, bDMC
mainly affected Sp1 chromatin recruitment following 24 h.
Cell death induced by bDMC is mediated by TOP2a
enzymatic and transcriptional targeting. To assess the
importance of TOP2A in mediating bDMC apoptotic
response, we knocked down TOP2A by transient RNAi.
TOP2A protein levels were reduced by 470% (Figure 7a)
and SubG1 events raised from 1.8 to 11.5% after small
interfering RNA (siRNA) transfection for 48 h (Figure 7b),
highlighting the fundamental role of TOP2A in HCT116
viability. Following bDMC administration, SubG1 events
raised to 6.3% in control cells, while no increase was
observed in TOP2A-deficient cells (from 11.5 to 8.7%),
although TOP2A protein levels were further reduced
(Figure 7a). On the other hand, the release from bDMC for
additional 24 h resulted in twofold increase of apoptosis also
in TOP2A knockdown cells (from 6.3 to 13.7% in control cells
and from 8.6 to 16.4% in silenced cells).
These data suggest that both enzymatic and transcriptional
TOP2A targeting contributes to bDMC cytotoxic activity. The
lack of an additive apoptotic effect of bDMC administration on
TOP2A-silenced cells, indicates that within the first 24 h an
important role is played by the enzymatic inhibition of TOP2A.
Reduced TOP2A levels avoid a further increase of apoptotic
events. Differently, TOP2A-depleted cells are still committed
to irreversible cell death when bDMC is removed, suggesting
that long-term apoptotic effects can be ascribed to TOP2A
transcriptional inhibition rather than its poisoning.
Discussion
High TOP2A levels result in enhanced proliferation rates of
many human malignancies and correlate with shortened
patient survival.51–53 These types of tumors are most
susceptible to TOP2-targeting chemotherapeutics. For these
reasons, TOP2A expression is a double-edged sword: on one
side, high TOP2A levels could indicate tumor aggressiveness
and poor outcome, on the other side, this could determine a
positive response to chemotherapeutic drugs targeting this
enzyme.
Our results provide evidence that bDMC suppresses cell
proliferation and induces apoptosis, at least in part, by
targeting TOP2A, thus encompassing bDMC in the category
of TOP2-based DNA-damaging agents. Indeed, bDMC
reduces cell viability by inducing DNA breaks and a persistent
and irreversible DNA damage response and inhibits TOP2A
activity as highlighted by MNase band-depletion and cell-free
TOP2A relaxation assays (Figure 4).
Interestingly, bDMC does not cause DNA damage-induced
cell death in normal cells, which are less susceptible to bDMC,
as highlighted by higher IC50 concentrations (Figure 2).
Tumor selectivity of Curcumin and its derivatives has been
already attributed to different mechanisms, such as lower
drug uptake in healthy cells,54 rather than increased sensi-
tivity of cancer cells due to lower glutathione levels or
constitutive expression of NF-kB.55 Taking into account that
tumor cells have normally higher expression of TOP2A
compared with normal cells, our data suggest that one of
the molecular basis for bDMC cancer cell selectivity and
susceptibility could be dependent on the levels of TOP2A
target protein.
TOP2A has a fundamental role in DNA replication, and it
has been shown that DNA damage induced by TOP2A
poisons is related to their interaction with DNA replication fork
progression.56 Although bDMC delays the progression from
early to late S phase,36 the majority of cells positive for gH2AX
following bDMC administration are accumulated in G2/M
phase (Figure 3), and chromosome aberrations are observed
in mitotic cells (Figure 3). DNA damage response and repair
are activated in G2/M cells, as demonstrated by the clear
reduction of the G2/M population following pre-treatment with
the PI3K-kinases inhibitor WORT (Figure 3). Surprisingly,
these cells escaping the G2/M DNA damage checkpoint are
not driven to apoptosis but are accumulated in the next G0/G1
phase, suggesting that apoptosis is triggered by a persistent
activation of the DNA damage response in G2/M cells.
Although 4- and 8-h treatment with bDMC induces a
concurrent inhibition of transcription and activity of TOP2A,
prolonged administration for 16 and 24 h results only in
reduced gene transcription (Figures 4 and 5). The inability of
long-term poisoning of TOP2A by bDMC could be due to the
rapid metabolism of the molecule inside the cell. After 24 h,
o0.5% of bDMC was detected inside the cells,36 and about
7.5% (±1.5) and 6.2% (±0.7) after 4 and 8 h, respectively
(data not shown). These data strongly suggest that the main
effects are induced by bDMC within 8 h, consistently with
maximum TOP2A enzymatic inhibition and reduced NF-Y
activity in 8 h, although the molecular mechanisms triggered
by bDMC or its metabolites, leading to TOP2A transcriptional
inhibition, could continue for longer time.
To shed light on the contribution of TOP2A poisoning rather
than transcriptional inhibition on apoptosis activation, we
silenced TOP2A through transient RNAi (Figure 7). TOP2A
knockdown leads to about sixfold increase of SubG1 events,
Figure 7 bDMC cytotoxic activity is mediated by Topoisomerases IIa enzymatic
and transcriptional targeting. (a) Western blot analysis of TOP2A following
siRNA-mediated knockdown of TOP2A and bDMC (30 mM) treatment for 24 h.
(b) Quantification of SubG1 population upon 30 mM bDMC treatment and release
(R) in control and TOP2A-inactivated cells
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and bDMC treatment for 24 h is not able to further augment
apoptosis, suggesting that direct TOP2A targeting contributes
to bDMC pro-apoptotic activity. The inhibition of mRNA levels,
and consequently of protein levels of TOP2A, has amajor role
in the irreversible activation of cell death, observed after drug
removal at 24 h.
TOP2A transcriptional inhibition results from decreased
recruitment of the transcription factor NF-Y to its regulatory
regions (Figure 5), as a consequence of halved NF-YA nuclear
levels and NF-YB/NF-YC cytoplasmic retention (Figure 6).
Despite a reduction of only 40 and 30% in the binding of NF-YA
and NF-YB, respectively, to TOP2A promoter, TOP2A gene
transcription is strongly affected by bDMC. This result is
consistent with our previous data observed in NF-YB-inacti-
vated cells: although NF-YB knockdown induces a robust
decrease of TOP2A levels, NF-YA and NF-YB binding were
reduced by about 20% compared with control cells.57
Finally, we showed that bDMC induces decreased expression
and chromatin recruitment of Sp1, important functional
partner of NF-Y in the control of TOP2A gene transcription
(Figure 6). These results are in agreement with (i) Sp1
downregulation observed upon NF-Y inactivation by gene
expression profiling,57 and (ii) ChIP-seq analysis (ENCODE
Data at UCSC Genome Browser) showing NF-Y binding to
Sp1 regulatory regions. All together, these data suggest that
NF-Y directly controls Sp1 transcription, and therefore, TOP2A
transcriptional downregulation induced by bDMC can be
ascribed to reduced NF-Y and, consequently, Sp1 levels.
In addition to the identification of TOP2A as one of the
molecular targets of bDMC, our data highlight that NF-Y
regulation can be an interesting approach in anti-cancer
therapy, taking into consideration that (i) NF-Y is one of the
transcription factors orchestrating oncogenic transcriptional
changes,58,59 and (ii) clinical studies correlated upregulated
expression of NF-Y target genes to poor clinical prognosis in
multiple types of cancer.60
Materials and Methods
Cell lines and treatments. Human colorectal carcinoma HCT116 cells were
cultured in Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with 10%
fetal calf serum (FCS). Human hepatic fetal epithelial WRL-68 cells and colon
adenocarcinoma LOVO cells were maintained in Dulbecco’s Modified Eagle
Medium (DMEM) with 10% FCS. Primary human fibroblasts (HF) were grown in
DMEM 10% FCS, with Glutamine (2 mM) and Gentamicin (55mg/l). Doubling time
has been estimated of about 16 h for HCT116, LOVO and WRL68 cells, and 24 h
for HF cells.
bDMC (1,7-bis[4-hydroxyphenyl]hepta-1,6-diene-3,5-dione) has been synthe-
sized as previously reported36 and added to warm medium at the indicated
concentrations. DMSO (Sigma-Aldrich Srl, Milan, Italy) was used as control. For
pharmacological inhibitions, cells were pre-treated for 1 h and then co-incubated
with bDMC for the indicated times with 25 mM Z-VAD-fmk (Enzo Life Sciences, Inc.,
Farmingdale, NY, USA), 10mM WORT (Enzo Life Sciences, Inc.), 1 mM MG132
(Sigma-Aldrich Srl), 20 mM NAC (Sigma-Aldrich Srl) and 10 ng/ml LMB (Enzo Life
Sciences, Inc.).
Crystal Violet assay. The inhibition of proliferation was measured by Crystal
Violet staining, and the concentration at which cellular growth is inhibited by 50%
(IC50) was determined following 24 h treatment with bDMC, as previously
reported.54 Briefly, the cell monolayer was fixed with methanol and stained with
0.05% Crystal Violet solution in 20% methanol for 1 h. After washes, cells were
allowed to dry. The incorporated dye was solubilized in acidic isopropanol and
determined spectrophotometrically at 540 nm wavelength. The extracted dye was
proportional to cell number.
Flow cytometric analysis. Cells were harvested after drug treatments at
the indicated time points and DNA distribution analysis of propidium iodide
(PI)-stained cells was performed by an Epics cytofluorimeter (Beckman Coulter
Srl, Milan, Italy).36 Apoptotic cells were detected by FACS using Annexin V-PE
conjugate (BD Biosciences, Becton Dickinson Italia, Milan, Italy) following the
protocol of the manufacturer.
Indirect immunofluorescence staining was performed as previously
described.57 Briefly, harvested cells were washed with PBS 1X, fixed in 1%
formaldehyde for 10 min at 37 1C and post-fixed with 90% ethanol. After
permeabilization with 0.25% Triton X-100 in PBS 1X for 5 min, cells were stained
with anti-phospho-H2AX Ser139 (No. 05-636, Millipore Spa, Vimodrone, Italy;
1 : 25) o.n. at 4 1C and with rabbit anti-mouse FITC-conjugated secondary
antibody (No. 0313, Dako Italia Spa, Milan, Italy; 1 : 50) for additional 2 h at 4 1C.
Following RNAse A treatment for 40 min, cells were incubated with PI (30 mg/ml)
for 30 min at 4 1C and analyzed by an Epics cytofluorimeter (Beckman Coulter
Srl).
Chromosome spreads. DMSO- and bDMC-treated cells were collected,
swollen in hypotonic solution (75mM KCl) and incubated for 10min at room
temperature. After two washes in Fix solution (3 : 1(vol/vol) methanol:acetic acid),
the cellular suspension was dropped on a wet ice-cold slide and stained for 15min
in Giemsa stain (No. 32884, Sigma-Aldrich Srl). Slides were washed in distilled
water, air-dried and mounted with DPX mountant (No. 44581, Sigma-Aldrich Srl).
Chromosomes were analyzed with a Nikon Eclipse 90i microscope (Nikon
Instruments Spa, Florence, Italy).
Immunoblotting. Whole-cell protein extracts were prepared by resuspending
cells into 1X SDS sample buffer (25mM Tris–HCl pH 6.8, 1.5 mM EDTA, 20%
glycerol, 2% SDS, 5% b-mercaptoethenol, 0.0025% Bromophenol blue). Nuclear
and cytoplasmic extracts were obtained by resuspending cells in 200ml of Solution
A (10mM HEPES pH7.9, 10mM KCl, 1.5 mM MgCl2, 0.34M sucrose, 10%
glycerol, protease and phosphatase inhibitors), adding 0.1% Triton X-100 and
incubating cells for 10min on ice. The supernatant containing cytoplasmic proteins
was collected by centrifugation at 1300 g for 5 min at 4 1C, and the remaining
pellet (nuclei) was disrupted in 1X SDS sample buffer (as above). Chromatin-
enriched extracts were prepared as previously described.57 For immunoblotting,
equivalent amounts of cellular extracts were resolved by SDS-PAGE, electro-
transferred to PVDF membrane (GE Healthcare Italia, Milan, Italy) and
immunoblotted. The following primary antibodies were used: anti-NF-YB and
anti-NF-YC purified rabbit polyclonal antibodies; anti-phospo-H2AX (sc-101696),
anti-H3 (C16) (sc-8654), anti-p53 (DO1) (sc-126), anti-TOP2A (K19) (sc-5347),
anti-PARP1 (F2) (sc-8007), anti-NF-YA (sc-10779), anti-Sp1 (sc-420 X) and anti-
actin (I19) (sc-1616) from Santa Cruz Biotecnology, Inc. (Dallas, TX, USA); anti-
phospho-ATM Ser1981 (No. 4526), anti-phospho-BRCA1 Ser1524 (No. 9009),
anti-phospho-Chk1 Ser296 (No. 2349) from Cell Signaling Technology, Inc.
(Danvers, MA, USA); and anti-a-tubulin (T6074) from Sigma-Aldrich Srl.
Chemiluminescent detection reagent has been purchased from Millipore Spa
(Luminata Classico and Forte Western HRP).
Immuno-band depletion assay. Briefly, 6 105 cells were lysed
in 50 ml of alkaline lysis solution (200 mMNaOH, 2 mM EDTA), and the lysate
was neutralized by 8 ml of neutralization buffer (1 M HCl, 600 mM Tris pH 8.0).
The neutralized lysate was mixed with 6.6 ml of 10MNase reaction
buffer (50 mM MgCl2, 50 mM CaCl2, 5 mM DTT, 1 mM EDTA, 1 mM PMSF,
protease inhibitors) and incubated or not with 60 units of MNase.
After 20 min digestion, 60 ml of 2SDS sample buffer were added to each
sample, and the lysates were separated on 8% SDS-PAGE gels and
immunoblotted.
TOP2 decatenation assay. TOP2 activity was assayed in vitro through the
Topoisomerse II assay kit (No. TG1001, TopoGEN Inc., Port Orange, FL, USA),
following the instructions of the manufacturer. Nuclear extracts containing TOP2
activity were obtained from HCT116 cells following the suggestions of the
manufacturer, and the ability to decatenate kDNA was analyzed in the presence of
DMSO and bDMC. Briefly, decatenation assay was performed with 50 ng kDNA in
a 10-ml reaction mixture containing 50mM Tris–HCl (pH 8.0), 150mM NaCl, 1
0 mM MgCl2, 0.5 mM dithiothreitol, 2 mM ATP, 30 mg/ml BSA with DMSO or 30,
60, 120mM of bDMC and 0.5mg of cell nuclear extract. Reactions were incubated
at 37 1C for 30min and stopped by adding 5 ml of stop buffer (5% Sarkosyl,
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0.125% bromphenol blue and 25% glycerol). Samples were loaded directly onto a
1% agarose gel containing ethidium bromide (0.5mg/ml). TOP2 activity was
measured by the appearance of decatenated minicircular products and determined
as the percentage of DMSO by ImageJ software (Image J, U.S. National Institutes
of Health, Bethesda, MD, USA).
RT-PCR. RNA was extracted from cells treated with DMSO and bDMC using
the Purelink RNA mini kit (Invitrogen, Life Technologies Italia, Monza, Italy)
according to the manufacturer’s protocol, and 3 mg of RNA were retro-transcribed
with a Moloney murine leukemia virus reverse transcriptase (Promega Italia SrL,
Milan, Italy). Semi-quantitative and quantitative real-time PCRs were performed
with oligonucleotides designed to amplify the cDNA of: GAPDH (forward
50-ACAGTCAGCCGCATCTTCTT-30; reverse 50-GCCCAATACGACCAAATCC-30),
TOP2A (forward 50-TGGCAGAGGCAGAGAGAGTT-30; reverse 50-TCAAAAAG
CACCATAGAGTTGC-30) and p21 (forward: 50-TGACCCTGAAGTGAGCACAG-30;
reverse: 50-GGGAAAAGGCTCAACACTGA-30). Semi-quantitative PCR results
were analyzed by ImageJ software, whereas relative fold change enrichments of
real-time PCR samples were calculated with the formula 2 (DDCt), where
 (DDCt)¼  ((CttargetCtGAPDH)bDMC (CttargetCtGAPDH)DMSO).
siRNA transfection. HCT116 cells were transfected (Metafectene SIþ ,
Biontex Laboratories GmbH, Martinsried/Planegg, Germany) with 300 nM of paired
TOP2A and non-targeting control siRNAs obtained from Sigma-Aldrich Srl. TOP2A
sense strand sequence: 50-AAGACTGTCTGTTGAAAGAA-30. Cells were analyzed
or treated with bDMC 36 h after transfection.
ChIPs. ChIPs were performed as previously described.54 In all, 4 mg of the
following antibodies were added to each IP and incubated overnight at 4 1C on a
rotating wheel: anti-H3Ac (No. 06-599, Millipore Spa), anti-H4Ac (No. 06-866,
Millipore Spa), anti-H3K4me3 (No. ab8580, AbCam, Cambridge, UK), anti-NF-YA
(No. sc-10779, Santa Cruz), anti-NF-YB purified polyclonal antibody and anti-
FLAG (No. F7425, Sigma-Aldrich Srl), used as control for non-specific interactions.
DNAs were resuspended in TE buffer, and PCR analyses were performed with the
following primers: p21 (forward: 50-GTAAATCCTTGCCTGCCAGAGTG-30;
reverse: 50-GCTGCCCAGCGCCGAGCCAG-30) and TOP2A (forward: 50-CGTCA
GAACAGAGGACAGTTTTT-30; reverse 50-TGGAAGAGATGGGCTTTGG-30).
Semi-quantitative PCR results were analyzed by ImageJ software. Relative fold
change enrichments of real-time quantitative PCR samples were calculated
with the formula 2 (DDCt), where DDCt¼  ((CtsampleCtinput)bDMC
(CtsampleCtinput)DMSO).
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